Get the Daily Brief
Latest Biotech News
FDA Expands Moderna’s RSV Vaccine Use in Adults
The FDA approved Moderna’s mRESVIA RSV vaccine for a broader adult at-risk population aged 18 to 59, following recent COVID-19 vaccine approvals. This expansion aims to provide preventive options...
Novel AML Treatment Combination Shows High Remission Rates
An early-phase trial at UNC Lineberger demonstrated that adding the menin inhibitor revumenib to standard azacitidine and venetoclax therapy yields high complete remission rates in AML patients...
Quantum Network Advances Redefining Precision Timing
A multi-national team achieved the most extensive coordinated comparison of optical atomic clocks over thousands of kilometers, operating ten different clock systems simultaneously. This work...
BioNTech Seals $1.25B Deal to Acquire CureVac’s mRNA Assets
BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating leadership in mRNA technology and expanding cancer immunotherapy capabilities. The deal, which offers...
Exercise Reverses Alzheimer’s Gene Dysregulation – Mouse Study
A single-nucleus RNA sequencing study reveals that exercise restores Alzheimer's-dysregulated gene expression in specific hippocampal cell types, notably immature neurons and disease-associated...
ADC Therapeutics Cuts UK R&D, Focuses Pipeline Amid Setbacks
Facing clinical failures and pipeline attrition, ADC Therapeutics announced a 30% workforce reduction, a U.K. research site closure, and discontinuation of some preclinical solid tumor programs....
BioNTech’s Strategic Acquisition: $1.25B CureVac Buyout
BioNTech has announced an all-stock acquisition of CureVac, valued at approximately $1.25 billion, aiming to consolidate its position in mRNA vaccine technology and oncology. The deal offers...
Alzheimer’s Disease Mechanisms and Exercise-Induced Neuroprotection
Recent studies elucidate distinct molecular contributions of amyloid-β and tau proteins to Alzheimer's disease pathology in central and peripheral tissues. Single-nucleus RNA sequencing of...
Parkinson’s Disease: Biomarkers and Genetic Insights
Emerging research highlights novel biomarkers and genetic factors influencing Parkinson’s disease onset, progression, and heterogeneity. Studies report elevated cerebrospinal fluid SERPIN E1...
AI and Computational Models Accelerating Drug Discovery and Disease Research
Artificial intelligence and computational modeling are increasingly transforming biotech research, from accelerating antiviral drug design against coronaviruses to enhancing antibody engineering...
Innovations in Neuroprosthetics and Brain-Computer Interfaces
Significant progress has been made in brain-computer interface (BCI) technology enabling communication and motor control for individuals with neurological impairments. Real-time neural decoding...
Breakthroughs in Plant Science and Crop Resilience
Recent advances redefine plant temperature sensing mechanisms, revealing decentralized genetic networks responsible for thermosensation, enabling design of climate-tailored crop varieties....
Drug Development and Therapeutic Advances
The biotech pipeline sees several notable developments including novel drug combinations demonstrating safety and efficacy in acute myeloid leukemia with specific genetic alterations, new...
Emerging Technologies in Biomanufacturing and Drug Screening
Novel platform technologies enhance biomanufacturing efficiency and drug screening capabilities. The collaboration between MaxCyte and Ori Biotech streamlines autologous cell therapy production,...
Environmental and Energy Innovations Addressing Climate Challenges
Innovative environmental solutions show promise in mitigating climate impacts. Dairy digesters in California effectively capture and reuse methane, reducing emissions by about 80%. In renewable...
Advances in Cancer Biology and Therapeutics
Cancer research progresses with insights into tumor plasticity, glycosaminoglycan-mediated lipoprotein uptake protecting tumors from ferroptosis, and novel gene therapy strategies targeting rare...
BioNTech buys CureVac in $1.25B stock pact ending mRNA dispute
BioNTech confirmed the acquisition of CureVac in a $1.25 billion all-stock deal that resolves ongoing mRNA patent litigation while enhancing its oncology pipeline. The agreement includes CureVac’s...
Instant voice-synthesis neuroprosthesis restores expressive speech
A pioneering brain-computer interface enabled a man with ALS to speak and sing naturally by synthesizing voice nearly instantaneously from neural signals, restoring expressive communication with...
ADC Therapeutics shutters UK R&D, cuts workforce by 30%
After discontinuing multiple clinical-stage programs due to poor efficacy, ADC Therapeutics is closing its UK research site and laying off 30% of staff to focus efforts on approved therapies and...
BioNTech Acquires CureVac in $1.25 Billion mRNA Deal
BioNTech has struck an all-stock agreement to acquire CureVac, a fellow German mRNA vaccine and cancer immunotherapy developer, for approximately $1.25 billion. The deal settles ongoing patent...